Authors find rivaroxaban not noninferior to vitamin K antagonists for secondary thromboprophylaxis.
American College of Cardiology 2013
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Anil Rajendra, MD, from the Medical University of South Carolina, in Charleston, SC, presented data showing similar bleeding and thrombotic complication rates at the time of atrial fibrillation ablation (AFA) in patients anticoagulated with dabigatran and rivaroxaban. Dr. Rajendra and colleagues determined that rivaroxaban has an acceptable safety profile for AFA.
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban
The 6-month cumulative VTE recurrence rate was 11 and 4% with dalteparin and rivaroxaban, respectively (hazard ratio, 0.43; 95% confidence interval, 0.19 to 0.99).
In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy.
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
Rivaroxaban given at doses of both 20mg and 15mg may have an improved bleeding risk profile compared with vitamin K antagponist.
American College of Cardiology 2011
Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but demonstrates weaker safety outcomes, according to results of the MAGELLAN trial presented today at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.